Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
Zheng CM, Wu CC, Hung CF, Liao MT, Shyu JF, Hsu YH, Lu CL, Wang YH, Zheng JQ, Chang TJ, Lin YF, Lu KC
Nutrients · 16 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-02-10 · Nutrients · vol. 10 · número 2 · pág. 196
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 19 citas · más que el 82% de estudios similares · 1.8× el promedio de su campo
- Referencias
- 52 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Parathyroid Disorders and Treatments · Vitamin D Research Studies · Pharmacological Effects and Toxicity Studies
- Palabras clave
- Cinacalcet, Calcitriol, Cholecalciferol, Secondary hyperparathyroidism, Medicine, Calcimimetic, Endocrinology, Internal medicine, Vitamin D and neurology, Hyperparathyroidism, Parathyroid hormone, Hemodialysis, Placebo, Urology, Calcium
- MeSH
- femur neck, humans, hyperparathyroidism, secondary, cholecalciferol, calcifediol, calcitriol, parathyroid hormone, vitamins, renal dialysis, severity of illness index, bone density, dietary supplements, aged, middle aged, female, male, calcimimetic agents, cinacalcet
12 autores
- Cai‐Mei Zheng🇹🇼Taipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Chia‐Chao Wu🇹🇼Tri-Service General Hospital; National Defense Medical Center
- Chi‐Feng Hung🇹🇼Fu Jen Catholic University
- Min-Tser Liao🇹🇼Tri-Service General Hospital; Taoyuan Armed Forces General Hospital; National Defense Medical Center
- Jia‐Fwu Shyu🇹🇼National Defense Medical Center
- Yung-Ho Hsu🇹🇼Taipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Chien‐Lin Lu🇹🇼Fu Jen Catholic University; Cardinal Tien Hospital; Taipei Medical University
- Yuan‐Hung Wang🇹🇼Taipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Jing-Quan Zheng🇹🇼Taipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Tian-Jong Chang🇹🇼Taipei Medical University-Shuang Ho Hospital; National Defense Medical Center
- Yuh‐Feng Lin🇹🇼 · autor de correspondenciaTaipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Kuo‐Cheng Lu🇹🇼 · autor de correspondenciaFu Jen Catholic University; Cardinal Tien Hospital; Taipei Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
We evaluated the improvement of intact parathyroid hormone (iPTH) levels and bone parameters by supplementing nutritional vitamin D (cholecalciferol) to combined calcimimetic (cinacalcet) and active vitamin D analog (calcitriol) among severe secondary hyperparathyroidism (SHPT) hemodialysis (HD) patients. A randomized, controlled open-label study was undertaken in 60 HD patients with serum iPTH > 1000 pg/mL or persistently high iPTH ≥ 600 pg/mL even after >3 months of calcitriol (3 μg/week). The study group received oral cholecalciferol (5000 IU/ day) and the control group received a placebo. All patients received fixed dose cinacalcet (30 mg/day, orally) and calcitriol. Calcitriol was reduced if iPTH ≤ 300 pg/mL and cinacalcet was withdrawn if serum iPTH was persistently low (iPTH ≤ 300 pg/mL) for 4 weeks after the reduction of calcitriol. A significantly lower iPTH level was noted from the 20th week in the study group compared to the placebo group, and the target iPTH ≤ 300 pg/mL was achieved at the 24th week in the study group. Most patients achieved serum 25-(OH)D₃ ≥ 30 ng/mL in the study group. Nearly 40% of study patients gained >10% improvement in femoral neck (FN) bone mineral density (BMD). We conclude that cholecalciferol additively reduced serum iPTH levels, improved 25-(OH)D₃ levels and improved FN BMD when used together with cinacalcet/calcitriol in severe SHPT HD patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.